Orofacial effects of antiretroviral therapies (Q34383790)

1 August 2017

1 reference

title

Orofacial effects of antiretroviral therapies (English)

1 reference

1 August 2017

main subject

anti-retroviral agent

0 references

1

Scully C

1 reference

1 August 2017

Diz Dios P

2

1 reference

1 August 2017

publication date

1 July 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

7

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

205-210

1 reference

Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

NNRTIs-a new class of drugs for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Gonorrhoea: an incidence graph of Mersey region data for the 1990s and discussion on the factors behind the changing pattern of incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

A controlled trial of zidovudine in primary human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

The HIV global pandemic: the development and emerging implication

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Fertility after a randomised trial of spontaneous abortion managed by surgical evacuation or expectant treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Genotypic-resistance assays and antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Changing prevalence of human immunodeficiency virus-associated oral lesions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Xerostomia associated with didanosine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

White lichenoid lesions of the buccal mucosa in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Cheilitis in association with indinavir

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Nail and mucocutaneous hyperpigmentation with azidothymidine therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Combination therapies for HIV infection and genomic drug resistance

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

HIV infection: oral lesions, CD4+ cell count and viral load in an Italian study population

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Parotid lipomatosis in HIV positive patients: a new clinical disorder associated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Didanosine as probable cause of Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

HIV topic update: protease inhibitor therapy and oral health care

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinica

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Effect of protease inhibitors on the sense of taste

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Effect of HAART on natural history of AIDS-related opportunistic disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

1 reference

7 January 2021

Oral manifestations of HIV infection in a group of predominantly ethnic Chinese

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Nevirapine-induced overlap stevens-johnson syndrome/toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2001.70401.X

7 January 2021

10.1034/J.1601-0825.2001.70401.X

Identifiers

DOI

1 reference

1 August 2017

1 reference